Direct comparative study of anti-IgE and anti-IL4Rα therapy effectiveness in patients with severe allergic and mixed bronchial asthma DOI Creative Commons
В. В. Наумова, Е. К. Beltyukov, О. П. Ковтун

et al.

Meditsinskiy sovet = Medical Council, Journal Year: 2024, Volume and Issue: 9, P. 74 - 86

Published: June 6, 2024

Introduction . There is insufficiency of direct comparative studies genetically engineered biological drugs (GEBD) for severe bronchial asthma (SA) treatment in scientific databases. Aim To compare omalizumab and dupilumab effectiveness patients with allergic mixed SA real clinical practice. Materials methods The study included an component from regional registry Sverdlovsk region. data (n = 68) 27) treated 62) 33) were analyzed. Therapy was determined 12 months general group No. 1, 2 3 according to the following indicators: control level (ACT), proportion uncontrolled asthma, need systemic glucocorticosteroids (SGCS) short‐acting beta agonists (SABA), basic therapy volume, exacerbations number, emergency calls hospitalizations, forced expiratory volume first second (FEV ), assessment life quality (AQLQ SNOT-22). Control evaluation visits conducted before start, after 4 biologics taking. Results In general, during targeted receiving statistically significant positive dynamics observed 13 evaluated indicators; – 9 indicators. When analyzing such indicators as, ACT, taking SGCS, SA, FEV , revealed all 3. Conclusions Patients respond equally well dupilumab. At same time, a tendency towards advantage phenotype disease revealed.

Language: Английский

Molecular Pathways and Potential Therapeutic Targets of Refractory Asthma DOI Creative Commons
Leah Ishmael, Thomas B. Casale, Juan Carlos Cardet

et al.

Biology, Journal Year: 2024, Volume and Issue: 13(8), P. 583 - 583

Published: Aug. 1, 2024

Asthma is a chronic inflammatory lung disease. Refractory asthma poses significant challenge in management due to its resistance standard therapies. Key molecular pathways of refractory include T2 inflammation mediated by Th2 and ILC2 cells, eosinophils, cytokines including IL-4, IL-5, IL-13. Additionally, non-T2 mechanisms involving neutrophils, macrophages, IL-1, IL-6, IL-17 mediate corticosteroid resistant phenotype. Mediators alarmins (IL-25, IL-33, TSLP) OX40L have overlap between may signify unique inflammation. Therapies that target these mediators proven be effective reducing exacerbations improving function subsets severe patients. However, there are patients with who do not respond approved Small molecule inhibitors, such as JAK-inhibitors, monoclonal antibodies targeting mast TNFα, under investigation for their potential modulate involved asthma. Understanding heterogeneity identifying essential developing therapeutic interventions unresponsive currently biologics. Further needed develop personalized treatments based on insights potentially offer more this complex

Language: Английский

Citations

4
Direct comparative study of anti-IgE and anti-IL4Rα therapy effectiveness in patients with severe allergic and mixed bronchial asthma DOI Creative Commons
В. В. Наумова, Е. К. Beltyukov, О. П. Ковтун

et al.

Meditsinskiy sovet = Medical Council, Journal Year: 2024, Volume and Issue: 9, P. 74 - 86

Published: June 6, 2024

Introduction . There is insufficiency of direct comparative studies genetically engineered biological drugs (GEBD) for severe bronchial asthma (SA) treatment in scientific databases. Aim To compare omalizumab and dupilumab effectiveness patients with allergic mixed SA real clinical practice. Materials methods The study included an component from regional registry Sverdlovsk region. data (n = 68) 27) treated 62) 33) were analyzed. Therapy was determined 12 months general group No. 1, 2 3 according to the following indicators: control level (ACT), proportion uncontrolled asthma, need systemic glucocorticosteroids (SGCS) short‐acting beta agonists (SABA), basic therapy volume, exacerbations number, emergency calls hospitalizations, forced expiratory volume first second (FEV ), assessment life quality (AQLQ SNOT-22). Control evaluation visits conducted before start, after 4 biologics taking. Results In general, during targeted receiving statistically significant positive dynamics observed 13 evaluated indicators; – 9 indicators. When analyzing such indicators as, ACT, taking SGCS, SA, FEV , revealed all 3. Conclusions Patients respond equally well dupilumab. At same time, a tendency towards advantage phenotype disease revealed.

Language: Английский

Citations

3